Cibinqo Shortage: What Providers and Prescribers Need to Know in 2026

Cibinqo (abrocitinib) is not in an active FDA-reported shortage in 2026. However, providers across dermatology, allergy, and immunology continue to encounter significant barriers when trying to get this medication into their patients' hands. Understanding the true nature of these barriers — and the available tools to overcome them — is essential for managing patients with moderate-to-severe atopic dermatitis who depend on this therapy.

Clinical Background: Why Cibinqo Matters for Your Patients

Cibinqo (abrocitinib) is a once-daily oral Janus kinase 1 (JAK1) inhibitor approved by the FDA in January 2022 for refractory, moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older. It is indicated when the disease is not adequately controlled with other systemic drug products including biologics, or when use of those therapies is inadvisable.

Abrocitinib's selectivity for JAK1 (28-fold over JAK2, >340-fold over JAK3) is thought to modulate key cytokines implicated in AD pathogenesis: IL-4, IL-13, IL-31, IL-22, and TSLP. In Phase 3 JADE trials, approximately 47.5% of patients on 200 mg and 32% on 100 mg achieved IGA 0/1 at 12 weeks. Its oral formulation makes it an important option for patients who are averse to or unable to receive biologic injections.

What's Actually Blocking Patient Access in 2026

Access barriers to Cibinqo are systemic, not supply-related:

Universal prior authorization. Virtually every commercial and Medicare Part D plan requires PA for Cibinqo as a specialty-tier drug. PA packages must typically document diagnosis, prior treatment failures, and medical necessity.

Step therapy mandates. Many formularies require documented failure on topical therapies and one or more systemic agents (often including dupilumab) before approving abrocitinib. This adds months to the approval timeline.

Specialty pharmacy fragmentation. Cibinqo is dispensed only through specialty pharmacies. Patients may face delays if their insurer's preferred specialty pharmacy has limited stock or slow processing times.

High cost exposure. With no generic abrocitinib available and retail pricing around $7,000–$7,100 per month, uninsured or underinsured patients face catastrophic out-of-pocket exposure.

Strategies to Streamline Prior Authorization for Cibinqo

The following approach has been shown to improve PA success rates and speed:

Submit PA simultaneously with the prescription. Don't wait for the pharmacy to trigger the PA request — proactively submit documentation at the point of prescribing.

Document prior treatment failures precisely. Include drug names, dates, doses, and documented inadequate response or intolerance. Vague documentation is the #1 cause of PA delays.

Invoke medical necessity exception for step therapy. If a patient has a contraindication to a required step-therapy drug (e.g., dupilumab), document this explicitly to bypass the step.

Request peer-to-peer review proactively. When PAs are denied, peer-to-peer review (physician calling the insurer medical director) often results in overturned denials.

Leverage Pfizer's hub services. Pfizer Dermatology Patient Access (1-833-956-3376) offers PA support services, specialty pharmacy coordination, and appeals assistance.

Pfizer Support Programs for Your Patients

Pfizer offers multiple programs that can help bridge the gap for your patients:

Cibinqo Copay Savings Card: Eligible commercially insured patients may pay as little as $0/month, with a maximum annual savings of up to $15,000. Enroll at cibinqo.com or call 1-833-956-3376.

Interim Care Rx bridge program: Commercially insured patients experiencing a PA delay or denial can receive up to 2 years of Cibinqo at no cost. Not available for Medicare or Medicaid patients.

Pfizer RxPathways: Patient assistance for uninsured or underinsured patients. Contact 844-989-7284.

37,512+ patients found their medications in stock

37K+

Find Cibinqo In Stock Today →

Pre-Prescribing Checklist for Cibinqo

Before initiating Cibinqo, ensure the following:

TB screening (IGRA or TST) and viral hepatitis screening

CBC at baseline (and again at 4 weeks and 4 weeks post dose increase)

Lipid panel at baseline; reassess at 4 weeks

Review renal function — reduce to 50 mg if moderate renal impairment (eGFR 30–59 mL/min); do not use in severe impairment

Platelet count threshold — do not initiate if platelets <150,000/mm3

CYP2C19 metabolizer status consideration — dose reduce to 50 mg in known poor metabolizers

Contraindication check: antiplatelet therapy use (contraindicated for first 3 months), active serious infection, pregnancy intent

How medfinder Supports Your Patients' Access

When your patients are having trouble finding Cibinqo at a nearby pharmacy, medfinder for providers can help. medfinder calls pharmacies near the patient's location to identify which ones carry the specific medication and dose. Results are delivered by text, helping patients get their prescriptions filled faster and reducing patient callbacks to your office.

See our full provider's guide to helping patients find Cibinqo in stock for more strategies.